JenaValve Technology said Monday that it has named David J. Drachman as CEO. The appointment is effective immediately. Drachman is the former president and CEO of AtriCure. Based in Munich, Germany and Irvine, Calif., JenaValve Technology is a provider of transcatheter aortic valve implantation systems that treat aortic valve disease. Its backers include Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.